Canada Pension Plan Investment Board raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 6.6% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,403,488 shares of the medical research company’s stock after buying an additional 211,653 shares during the quarter. Canada Pension Plan Investment Board owned about 1.87% of IQVIA worth $719,634,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of IQV. Rise Advisors LLC purchased a new stake in IQVIA in the 1st quarter worth approximately $31,000. Versant Capital Management Inc raised its position in shares of IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after buying an additional 110 shares in the last quarter. Riverview Trust Co bought a new stake in IQVIA during the first quarter valued at $32,000. Opal Wealth Advisors LLC purchased a new position in IQVIA during the second quarter worth about $27,000. Finally, International Assets Investment Management LLC bought a new position in IQVIA in the 2nd quarter worth about $32,000. 89.62% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.60% of the stock is currently owned by insiders.
Analysts Set New Price Targets
View Our Latest Analysis on IQVIA
IQVIA Price Performance
Shares of IQVIA stock opened at $244.62 on Friday. The company’s fifty day simple moving average is $240.24 and its two-hundred day simple moving average is $234.25. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73. The firm has a market cap of $44.57 billion, a PE ratio of 33.42, a price-to-earnings-growth ratio of 2.24 and a beta of 1.49. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80.
IQVIA (NYSE:IQV – Get Free Report) last announced its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion. During the same quarter in the previous year, the business earned $2.22 EPS. IQVIA’s revenue was up 2.3% compared to the same quarter last year. As a group, equities analysts expect that IQVIA Holdings Inc. will post 10.25 EPS for the current year.
IQVIA Profile
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also
- Five stocks we like better than IQVIA
- Want to Profit on the Downtrend? Downtrends, Explained.
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Where to Find Earnings Call Transcripts
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- The Role Economic Reports Play in a Successful Investment Strategy
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.